ParenteralDosed ingredient
Cosmetic cross-reference
Ioversol
CAS 87771-40-2
Ioversol (CAS 87771-40-2) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 240 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
2
SOURCE
DrugCentral
Adverse signals
240
SOURCE
IUPHAR/BPS
PubMed IDs
0
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Ioversol
CAS Number
87771-40-2
UNII
N3RIB7X24K
InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1200614
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
black box warningdosed ingredientnatural productparenteral
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1200614 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
EMBL-EBI ChEMBL
2 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 3183.25 nM | 2 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
SOURCE
DrugCentral
49 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Urticaria | 503 | 1145.065 | 10046735 |
| Sneezing | 190 | 669.01 | 10041232 |
| Nephropathy toxic | 179 | 605.659 | 10029155 |
| Throat irritation | 194 | 537.337 | 10043521 |
| Pruritus | 403 | 533.113 | 10037087 |
| Anaphylactic shock | 145 | 400.381 | 10002199 |
| Throat tightness | 129 | 361.652 | 10043528 |
| Contrast media reaction | 64 | 307.227 | 10010836 |
| Dyspnoea | 406 | 298.057 | 10013968 |
| Air embolism | 43 | 249.834 | 10001526 |
| Erythema | 191 | 236.176 | 10015150 |
| Chest discomfort | 142 | 198.263 | 10008469 |
| Eye pruritus | 76 | 191.283 | 10052140 |
| Laryngeal oedema | 53 | 167.329 | 10023845 |
| Pharyngeal oedema | 63 | 165.829 | 10034829 |
| Rash | 243 | 130.904 | 10037844 |
| Laryngeal discomfort | 25 | 127.657 | 10054115 |
| Anaphylactic reaction | 89 | 125.356 | 10002198 |
| Eye swelling | 58 | 117.678 | 10015967 |
| Bronchospasm | 54 | 115.122 | 10006482 |
| Type I hypersensitivity | 33 | 111.734 | 10045240 |
| Cough | 165 | 110.669 | 10011224 |
| Shock | 60 | 103.998 | 10040560 |
| Cyanosis | 49 | 97.913 | 10011703 |
| Oral pruritus | 27 | 96.379 | 10052894 |
| Ocular hyperaemia | 52 | 96.06 | 10030041 |
| Eyelid oedema | 39 | 93.142 | 10015993 |
| Extravasation | 29 | 92.832 | 10015866 |
| Product administration error | 51 | 87.543 | 10081576 |
| Drug ineffective | 18 | 82.971 | 10013709 |
| Nasal congestion | 64 | 77.852 | 10028735 |
| Anaphylactoid reaction | 27 | 77.66 | 10002216 |
| Hypersensitivity | 126 | 77.098 | 10020751 |
| Injection site extravasation | 32 | 75.635 | 10022062 |
| Fatigue | 12 | 74.223 | 10016256 |
| Lip swelling | 48 | 73.641 | 10024570 |
| Blood pressure decreased | 69 | 73.555 | 10005734 |
| Flushing | 66 | 71.763 | 10016825 |
| Loss of consciousness | 83 | 64.878 | 10024855 |
| Off label use | 15 | 63.806 | 10053762 |
| Procedural complication | 26 | 62.883 | 10057765 |
| Hypoaesthesia oral | 30 | 60.763 | 10057371 |
| Paraesthesia oral | 33 | 59.75 | 10057372 |
| Oxygen saturation decreased | 71 | 58.831 | 10033318 |
| Cardio-respiratory arrest | 61 | 58.761 | 10007617 |
| Swollen tongue | 40 | 53.732 | 10042727 |
| Feeling hot | 46 | 52.688 | 10016334 |
| Dysphonia | 46 | 52.283 | 10013952 |
| Face oedema | 33 | 51.783 | 10016029 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
NLM RxNorm
2 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| IOVERSOL | 27792 | SU | MTHSPL |
| ioversol | 27792 | IN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Acidosis | ioversol | LLT | C0001122 |
| Acidosis | ioversol | PT | C0001122 |
| Acute coronary syndrome | ioversol | PT | C0948089 |
| Agitation | ioversol | LLT | C0085631 |
| Agitation | ioversol | PT | C0085631 |
| Amnesia | ioversol | LLT | C0002622 |
| Amnesia | ioversol | PT | C0002622 |
| Anaphylactic shock | ioversol | LLT | C0002792 |
| Anaphylactic shock | ioversol | PT | C0002792 |
| Angina pectoris | ioversol | LLT | C0002962 |
| Angina pectoris | ioversol | PT | C0002962 |
| Angioedema | ioversol | LLT | C0002994 |
| Angioedema | ioversol | PT | C0002994 |
| Anoxia | ioversol | LLT | C0003130 |
| Anoxia | ioversol | PT | C0003130 |
| Anuria | ioversol | LLT | C0003460 |
| Anuria | ioversol | PT | C0003460 |
| Anxiety | ioversol | LLT | C0003467 |
| Anxiety | ioversol | PT | C0003467 |
| Aortic valve stenosis | ioversol | LLT | C0003507 |
| Aortic valve stenosis | ioversol | PT | C0003507 |
| Aphasia | ioversol | LLT | C0003537 |
| Aphasia | ioversol | PT | C0003537 |
| Aphasia | ioversol | PT | C0003537 |
| Apnoea | ioversol | LLT | C0003578 |
| Apnoea | ioversol | PT | C0003578 |
| Arrhythmia | ioversol | LLT | C0003811 |
| Arrhythmia | ioversol | PT | C0003811 |
| Arterial occlusion | ioversol | LLT | C0264995 |
| Arterial occlusive disease | ioversol | PT | C0003838 |
| Arterial spasm | ioversol | LLT | C0085617 |
| Arterial spasm | ioversol | PT | C0085617 |
| Arterial thrombosis | ioversol | LLT | C0151942 |
| Arterial thrombosis | ioversol | PT | C0151942 |
| Arteriosclerosis | ioversol | PT | C0003850 |
| Arteriosclerosis | ioversol | PT | C0003850 |
| Arteriovenous fistula | ioversol | LLT | C0003855 |
| Arteriovenous fistula | ioversol | PT | C0003855 |
| Artery dissection | ioversol | LLT | C0002949 |
| Artery dissection | ioversol | PT | C0002949 |
| Asthma | ioversol | PT | C0004096 |
| Asthmatic attack | ioversol | LLT | C0347950 |
| Atheroma | ioversol | LLT | C0264956 |
| Atherosclerosis | ioversol | LLT | C0004153 |
| Atrioventricular block | ioversol | PT | C0004245 |
| Bad taste | ioversol | LLT | C0541799 |
| Blindness | ioversol | LLT | C0456909 |
| Blindness | ioversol | PT | C0456909 |
| Blindness cortical | ioversol | LLT | C0155320 |
| Blindness cortical | ioversol | PT | C0155320 |
| Block heart | ioversol | LLT | C0018794 |
| Blood pressure fluctuation | ioversol | LLT | C0549405 |
| Blood pressure fluctuation | ioversol | PT | C0549405 |
| Body temperature increased | ioversol | LLT | C0015967 |
| Body temperature increased | ioversol | PT | C0015967 |
| Bradycardia | ioversol | LLT | C0428977 |
| Bradycardia | ioversol | PT | C0428977 |
| Bronchospasm | ioversol | LLT | C0006266 |
| Bronchospasm | ioversol | PT | C0006266 |
| Bundle branch block | ioversol | LLT | C0006384 |
| Bundle branch block | ioversol | PT | C0006384 |
| Cardiac arrest | ioversol | LLT | C0018790 |
| Cardiac arrest | ioversol | PT | C0018790 |
| Cardiac failure | ioversol | PT | C0018801 |
| Cardiac tamponade | ioversol | LLT | C0007177 |
| Cardiac tamponade | ioversol | PT | C0007177 |
| Cardio-respiratory arrest | ioversol | LLT | C0600228 |
| Cardio-respiratory arrest | ioversol | PT | C0600228 |
| Cardiogenic shock | ioversol | LLT | C0036980 |
| Cardiogenic shock | ioversol | PT | C0036980 |
| Cardiovascular disorder | ioversol | LLT | C0007222 |
| Cardiovascular disorder | ioversol | PT | C0007222 |
| Cerebral infarction | ioversol | LLT | C0007785 |
| Cerebral infarction | ioversol | PT | C0007785 |
| Cerebrovascular accident | ioversol | LLT | C0038454 |
| Cerebrovascular accident | ioversol | PT | C0038454 |
| Chest pain | ioversol | LLT | C0008031 |
| Chest pain | ioversol | PT | C0008031 |
| Chills | ioversol | LLT | C0085593 |
| Chills | ioversol | PT | C0085593 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ioversol used for in pharmaceutical contexts?
Ioversol (CAS 87771-40-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ioversol?
Ioversol has 240 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Urticaria, Sneezing, Nephropathy toxic, Throat irritation, Pruritus. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ioversol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Rumex Occidentalis Extract with EU status "permitted".
What clinical phase is Ioversol in?
Ioversol is rendered with ChEMBL max phase 4 (approved).